In the present study, we focused on the translational potential of RGS in KRAS-mutant colorectal cancer treatment; the selective anti-tumor effect of RGS in KRAS mutant CRC was comprehensively studied, for the first time, in models ranging from cancer cell lines to patient-derived xenograft models. The gene discussed is PITX2; the disease is cancer.